vs

Side-by-side financial comparison of Phreesia, Inc. (PHR) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

REPLIGEN CORP is the larger business by last-quarter revenue ($197.9M vs $120.3M, roughly 1.6× Phreesia, Inc.). REPLIGEN CORP runs the higher net margin — 6.7% vs 3.5%, a 3.2% gap on every dollar of revenue. On growth, REPLIGEN CORP posted the faster year-over-year revenue change (13.6% vs 12.7%). REPLIGEN CORP produced more free cash flow last quarter ($17.6M vs $12.2M).

Phreesia, Inc. is a software as a service company that offers healthcare organizations a set of applications to automate and manage patient intake.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

PHR vs RGEN — Head-to-Head

Bigger by revenue
RGEN
RGEN
1.6× larger
RGEN
$197.9M
$120.3M
PHR
Growing faster (revenue YoY)
RGEN
RGEN
+1.0% gap
RGEN
13.6%
12.7%
PHR
Higher net margin
RGEN
RGEN
3.2% more per $
RGEN
6.7%
3.5%
PHR
More free cash flow
RGEN
RGEN
$5.4M more FCF
RGEN
$17.6M
$12.2M
PHR

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
PHR
PHR
RGEN
RGEN
Revenue
$120.3M
$197.9M
Net Profit
$4.3M
$13.3M
Gross Margin
52.5%
Operating Margin
3.1%
9.0%
Net Margin
3.5%
6.7%
Revenue YoY
12.7%
13.6%
Net Profit YoY
129.7%
143.9%
EPS (diluted)
$0.07
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PHR
PHR
RGEN
RGEN
Q4 25
$120.3M
$197.9M
Q3 25
$117.3M
$188.8M
Q2 25
$115.9M
$182.4M
Q1 25
$169.2M
Q4 24
$174.1M
Q3 24
$154.9M
Q2 24
$154.1M
Q1 24
$151.3M
Net Profit
PHR
PHR
RGEN
RGEN
Q4 25
$4.3M
$13.3M
Q3 25
$654.0K
$14.9M
Q2 25
$-3.9M
$14.9M
Q1 25
$5.8M
Q4 24
$-30.3M
Q3 24
$-654.0K
Q2 24
$3.3M
Q1 24
$2.1M
Gross Margin
PHR
PHR
RGEN
RGEN
Q4 25
52.5%
Q3 25
53.2%
Q2 25
50.0%
Q1 25
53.6%
Q4 24
26.1%
Q3 24
50.0%
Q2 24
49.8%
Q1 24
49.5%
Operating Margin
PHR
PHR
RGEN
RGEN
Q4 25
3.1%
9.0%
Q3 25
-1.3%
8.9%
Q2 25
-2.8%
7.6%
Q1 25
3.9%
Q4 24
-17.7%
Q3 24
-5.1%
Q2 24
1.0%
Q1 24
1.3%
Net Margin
PHR
PHR
RGEN
RGEN
Q4 25
3.5%
6.7%
Q3 25
0.6%
7.9%
Q2 25
-3.4%
8.2%
Q1 25
3.4%
Q4 24
-17.4%
Q3 24
-0.4%
Q2 24
2.2%
Q1 24
1.4%
EPS (diluted)
PHR
PHR
RGEN
RGEN
Q4 25
$0.07
$0.24
Q3 25
$0.01
$0.26
Q2 25
$-0.07
$0.26
Q1 25
$0.10
Q4 24
$-0.55
Q3 24
$-0.01
Q2 24
$0.06
Q1 24
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PHR
PHR
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$106.4M
$767.6M
Total DebtLower is stronger
$3.4M
$542.2M
Stockholders' EquityBook value
$320.3M
$2.1B
Total Assets
$423.5M
$2.9B
Debt / EquityLower = less leverage
0.01×
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PHR
PHR
RGEN
RGEN
Q4 25
$106.4M
$767.6M
Q3 25
$98.3M
$748.7M
Q2 25
$90.9M
$708.9M
Q1 25
$697.2M
Q4 24
$757.4M
Q3 24
$784.0M
Q2 24
$809.1M
Q1 24
$780.6M
Total Debt
PHR
PHR
RGEN
RGEN
Q4 25
$3.4M
$542.2M
Q3 25
$4.6M
$537.9M
Q2 25
$6.2M
Q1 25
Q4 24
$525.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
PHR
PHR
RGEN
RGEN
Q4 25
$320.3M
$2.1B
Q3 25
$298.0M
$2.1B
Q2 25
$282.2M
$2.1B
Q1 25
$2.0B
Q4 24
$2.0B
Q3 24
$2.0B
Q2 24
$2.0B
Q1 24
$2.0B
Total Assets
PHR
PHR
RGEN
RGEN
Q4 25
$423.5M
$2.9B
Q3 25
$408.6M
$2.9B
Q2 25
$400.4M
$2.9B
Q1 25
$2.9B
Q4 24
$2.8B
Q3 24
$2.8B
Q2 24
$2.9B
Q1 24
$2.8B
Debt / Equity
PHR
PHR
RGEN
RGEN
Q4 25
0.01×
0.26×
Q3 25
0.02×
0.26×
Q2 25
0.02×
Q1 25
Q4 24
0.27×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PHR
PHR
RGEN
RGEN
Operating Cash FlowLast quarter
$15.5M
$25.7M
Free Cash FlowOCF − Capex
$12.2M
$17.6M
FCF MarginFCF / Revenue
10.1%
8.9%
Capex IntensityCapex / Revenue
2.7%
4.1%
Cash ConversionOCF / Net Profit
3.62×
1.93×
TTM Free Cash FlowTrailing 4 quarters
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PHR
PHR
RGEN
RGEN
Q4 25
$15.5M
$25.7M
Q3 25
$14.8M
$48.1M
Q2 25
$14.8M
$28.6M
Q1 25
$15.0M
Q4 24
$39.2M
Q3 24
$49.3M
Q2 24
$42.2M
Q1 24
$44.7M
Free Cash Flow
PHR
PHR
RGEN
RGEN
Q4 25
$12.2M
$17.6M
Q3 25
$13.1M
$43.4M
Q2 25
$11.3M
$21.5M
Q1 25
$11.4M
Q4 24
$33.6M
Q3 24
$42.3M
Q2 24
$37.4M
Q1 24
$36.4M
FCF Margin
PHR
PHR
RGEN
RGEN
Q4 25
10.1%
8.9%
Q3 25
11.1%
23.0%
Q2 25
9.8%
11.8%
Q1 25
6.8%
Q4 24
19.3%
Q3 24
27.3%
Q2 24
24.3%
Q1 24
24.0%
Capex Intensity
PHR
PHR
RGEN
RGEN
Q4 25
2.7%
4.1%
Q3 25
1.5%
2.5%
Q2 25
3.0%
3.9%
Q1 25
2.1%
Q4 24
3.2%
Q3 24
4.5%
Q2 24
3.1%
Q1 24
5.5%
Cash Conversion
PHR
PHR
RGEN
RGEN
Q4 25
3.62×
1.93×
Q3 25
22.68×
3.23×
Q2 25
1.92×
Q1 25
2.57×
Q4 24
Q3 24
Q2 24
12.70×
Q1 24
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PHR
PHR

Subscription And Services$55.5M46%
Network Solutions$37.4M31%
Payment Processing Fees$27.4M23%

RGEN
RGEN

Segment breakdown not available.

Related Comparisons